Long-Term Nirogacestat for Progressive Desmoid Tumors: Durable Responses, Continued Tumor Shrinkage, and a Manageable Safety Profile
Posted inHematology-Oncology news Oncology

Long-Term Nirogacestat for Progressive Desmoid Tumors: Durable Responses, Continued Tumor Shrinkage, and a Manageable Safety Profile

Extended follow-up from the phase III DeFi trial shows that continuous nirogacestat yields further tumor shrinkage, durable objective responses (ORR 45.7% at up to 4 years), sustained patient-reported benefits, and a consistent, manageable safety profile over a median 33.6 months of exposure.
PASS-01: Gemcitabine/Nab‑Paclitaxel Shows an Overall Survival Edge Over Modified FOLFIRINOX in First‑Line Metastatic PDAC — Biomarker Correlatives Underscore Need to Move Precision Upstream
Posted innews Oncology

PASS-01: Gemcitabine/Nab‑Paclitaxel Shows an Overall Survival Edge Over Modified FOLFIRINOX in First‑Line Metastatic PDAC — Biomarker Correlatives Underscore Need to Move Precision Upstream

In the randomized phase II PASS‑01 trial of first‑line metastatic pancreatic ductal adenocarcinoma (PDAC), progression‑free survival was similar between modified FOLFIRINOX and gemcitabine/nab‑paclitaxel, but overall survival and safety trends favored gemcitabine/nab‑paclitaxel. Molecular profiling and organoid work were feasible but second‑line, correlate‑guided therapy showed limited benefit.
Neoadjuvant 177Lu-PSMA Before SBRT Doubles Progression-Free Survival in Oligorecurrent Hormone-Sensitive Prostate Cancer — Results from the LUNAR Phase II Trial
Posted innews Oncology Urology

Neoadjuvant 177Lu-PSMA Before SBRT Doubles Progression-Free Survival in Oligorecurrent Hormone-Sensitive Prostate Cancer — Results from the LUNAR Phase II Trial

In the randomized phase II LUNAR trial, adding two cycles of neoadjuvant 177Lu-PNT2002 to stereotactic body radiotherapy (SBRT) for oligorecurrent hormone-sensitive prostate cancer significantly prolonged progression-free survival (17.6 vs 7.4 months; HR 0.37) without increased grade ≥3 toxicity.
Neoadjuvant TQB2102 (Bispecific HER2-Directed ADC) Produces High Pathologic Complete Response Rates in Early and Locally Advanced HER2-Positive Breast Cancer
Posted innews Oncology

Neoadjuvant TQB2102 (Bispecific HER2-Directed ADC) Produces High Pathologic Complete Response Rates in Early and Locally Advanced HER2-Positive Breast Cancer

A randomized phase II trial of the bispecific HER2-directed ADC TQB2102 (n=104) showed robust total pathologic complete response rates (tpCR 57.7–76.9% across cohorts) with manageable grade ≥3 toxicity and no treatment‑related deaths, supporting further comparative evaluation.
Eflornithine Plus Lomustine Extends Progression-Free and Overall Survival in Recurrent IDH‑Mutant Grade 3 Astrocytoma — Results from STELLAR Phase III
Posted inNeurology news Oncology

Eflornithine Plus Lomustine Extends Progression-Free and Overall Survival in Recurrent IDH‑Mutant Grade 3 Astrocytoma — Results from STELLAR Phase III

The STELLAR phase III trial found that eflornithine added to lomustine doubled PFS and significantly improved OS in patients with recurrent IDH‑mutant grade 3 astrocytoma after radiotherapy and temozolomide, with increased but manageable myelosuppression and hearing toxicity.
Minimally Invasive Pancreatoduodenectomy Is Noninferior to Open Surgery for 90‑Day Complications but Raises Important Safety and Generalizability Questions
Posted inGeneral Surgery news Oncology

Minimally Invasive Pancreatoduodenectomy Is Noninferior to Open Surgery for 90‑Day Complications but Raises Important Safety and Generalizability Questions

An international randomized trial found minimally invasive pancreatoduodenectomy (mostly robotic) noninferior to open surgery for 90‑day overall complications and modestly faster functional recovery, with lower fistula and wound‑infection rates but a numerically higher 90‑day mortality.
Low‑Dose IL‑2 after Lymphodepletion and TIL Infusion Offers Comparable Immune and Clinical Outcomes to High‑Dose IL‑2 in Metastatic Melanoma
Posted innews Oncology

Low‑Dose IL‑2 after Lymphodepletion and TIL Infusion Offers Comparable Immune and Clinical Outcomes to High‑Dose IL‑2 in Metastatic Melanoma

A phase II study in metastatic melanoma found no major differences in response, circulating T‑cell phenotypes, or proliferative signals between high‑dose and low‑dose IL‑2 after lymphodepletion and tumor‑infiltrating lymphocyte (TIL) infusion followed by pembrolizumab, suggesting low‑dose IL‑2 may be a feasible, lower‑toxicity alternative.
Preoperative Pembrolizumab Plus Chemoradiotherapy (PPCT) for Locally Advanced Resectable ESCC: PALACE‑2 Phase 1/2 Results and Immune‑Microenvironment Insights
Posted innews Oncology

Preoperative Pembrolizumab Plus Chemoradiotherapy (PPCT) for Locally Advanced Resectable ESCC: PALACE‑2 Phase 1/2 Results and Immune‑Microenvironment Insights

PALACE‑2 reports that preoperative pembrolizumab combined with chemoradiotherapy produced a 43.2% pathologic complete response in resectable, locally advanced esophageal squamous cell carcinoma, with acceptable short‑term survival and a high rate of grade ≥3 toxicities; IL‑6 emerged as a potential predictive and targetable mediator of response.